Tcfcp211の2nd intronにgene-trapが挿入されたライン。全長 mRNA およびタンパク質の量ともに大幅に減少している。ホモ個体の一部は成体まで生存、繁殖可能。 C (3-6 months) mouse Tcfcp2l1 genomic DNA, pSAβgeo Heterozygote x Wild-type [C57BL/6JJcl] 繁殖成績が低い ホモで不妊／死亡 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Dev. Dyn., 233, 484-495 (2005). Development,133, 4737-4348 (2006).<br>寄託者（開発者）の承諾を得る。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 岡崎統合バイオサイエンスセンター 山口良文先生、高田慎治先生 (2005)。CJ7 (129S1/Sv-Oca2<+> Tyr<+> Kitl<+>) ES細胞由来。C57BL/6Jにコンジェニックされた (N11以上)。 true B6.129S1-Tcfcp2l1<Gt(pLSABetageo)1Sjt> B6.129S1-Tcfcp2l1<Gt(pLSABetageo)1Sjt> Shinji TAKADA Developed by Yoshifumi Yamaguchi and Shinji Takada, Okazaki Institute for Integrative Bioscience in 2005. CJ7 (129S1/Sv-Oca2<+> Tyr<+> Kitl<+>) ES cells derived. The mutant mice were backcrossed to C57BL/6J over 11 times. C（3〜6か月） Heterozygote x Wild-type [C57BL/6JJcl] <a href='https://brc.riken.jp/mus/pcr03117'>Genotyping protocol -PCR-</a> Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> Tcfcp211trap Tcfcp211trap RBRC03117 Tcfcp2l1 gene trapped mice. The pLSABetageo vector was inserted in the second intron of Tcfcp2l1 gene. Homozygous mutant mice show a partial postnatal lethality. Heterozygote x Wild-type [C57BL/6JJcl]繁殖成績が低いホモで不妊／死亡 In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Dev. Dyn., 233, 484-495 (2005). Development,133, 4737-4348 (2006).The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEPOSITOR/DEVELOPER. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. 高田　慎治